pimecrolimus

Contraindicated in:

Hypersensitivity;
Should not be applied to areas of active cutaneous viral infections (↑ risk of dissemination);
Concurrent use of occlusive dressings;
Netherton’s syndrome (↑ absorption of pimecrolimus);
Lactation: Lactation.

Use Cautiously in:

Clinical infection at treatment site (infection should be treated/cleared prior to use);
Skin papillomas (warts); allow treatment/resolution prior to use;
Natural/artificial sunlight (minimize exposure);
OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Pedi: Children <2 yr (safety and effectiveness not established).

Adv. Reactions/Side Effects ⬆ ⬇

Local: burning

Misc: ↑risk of lymphoma/skin cancer

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

(Generic available)

Cream: 1%

Route/Dosage ⬆ ⬇

(Adults and Children ≥2 yr): Apply thin film twice daily; rub in gently and completely.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Inhibits T-cell and mast cell activation by interfering with production of inflammatory cytokines.

Therapeutic effects:

Decreased severity of atopic dermatitis.

Classifications ⬆ ⬇

Therapeutic Classification: Immunosuppressant agents (topical)

Pharmacokinetics ⬆ ⬇

Absorption: Minimally absorbed through intact skin.

Distribution: Local distribution after topical administration.

Metabolism/Excretion: Systemic metabolism and excretion are negligible with local application.

Half-Life: Not applicable.

Time/Action Profile ⬆ ⬇

(improvement in symptoms)

ROUTE	ONSET	PEAK	DURATION
topical	within 6 days	unknown	unknown

Patient/Family Teaching ⬆ ⬇

Instruct patient on correct technique for application. Apply only as directed to external areas. Wash hands following application, unless hands are areas of application. Advise patient to read Medication Guide before starting and with each Rx refill in case of changes.
Caution patient to avoid exposure to natural or artificial sunlight, including tanning beds, while using cream.
Advise patient that pimecrolimus may cause skin burning. This occurs most commonly during 1st few days of application, is of mild to moderate severity, and improves within 5 days or as atopic dermatitis resolves.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
Advise patient to notify health care provider if no improvement is seen following 6 wk of treatment or at any time if condition worsens.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0187- Bausch Health US LLC
- 0187-5100- ELIDEL
  - 0187-5100-01- 1 TUBE in 1 CARTON (0187-5100-01) > 30 g in 1 TUBE

0187- Bausch Health US LLC
- 0187-5101- ELIDEL
  - 0187-5101-02- 1 TUBE in 1 CARTON (0187-5101-02) > 60 g in 1 TUBE

0187- Bausch Health US LLC
- 0187-5102- ELIDEL
  - 0187-5102-03- 1 TUBE in 1 CARTON (0187-5102-03) > 100 g in 1 TUBE

0187- Bausch Health US LLC
- 0187-5103- ELIDEL
  - 0187-5103-04- 1 TUBE in 1 CARTON (0187-5103-04) > 5 g in 1 TUBE

0591- Actavis Pharma, Inc.
- 0591-2944- pimecrolimus
  - 0591-2944-30- 30 g in 1 TUBE (0591-2944-30)

0591- Actavis Pharma, Inc.
- 0591-2944- pimecrolimus
  - 0591-2944-60- 60 g in 1 TUBE (0591-2944-60)

0591- Actavis Pharma, Inc.
- 0591-2944- pimecrolimus
  - 0591-2944-87- 100 g in 1 TUBE (0591-2944-87)

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-609- Pimecrolimus
  - 68462-609-35- 1 TUBE in 1 CARTON (68462-609-35) > 30 g in 1 TUBE

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-609- Pimecrolimus
  - 68462-609-65- 1 TUBE in 1 CARTON (68462-609-65) > 60 g in 1 TUBE

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-609- Pimecrolimus
  - 68462-609-94- 1 TUBE in 1 CARTON (68462-609-94) > 100 g in 1 TUBE

68682- Oceanside Pharmaceuticals
- 68682-110- Pimecrolimus
  - 68682-110-01- 1 TUBE in 1 CARTON (68682-110-01) > 30 g in 1 TUBE

68682- Oceanside Pharmaceuticals
- 68682-111- Pimecrolimus
  - 68682-111-02- 1 TUBE in 1 CARTON (68682-111-02) > 60 g in 1 TUBE

68682- Oceanside Pharmaceuticals
- 68682-112- Pimecrolimus
  - 68682-112-03- 1 TUBE in 1 CARTON (68682-112-03) > 100 g in 1 TUBE

70518- REMEDYREPACK INC.
- 70518-2292- pimecrolimus
  - 70518-2292-0- 30 g in 1 TUBE (70518-2292-0)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇